医学
嵌合抗原受体
造血干细胞移植
免疫学
干细胞
移植
免疫系统
造血细胞
抗原
造血
T细胞
癌症研究
内科学
生物
遗传学
作者
Guanhua Hu,Ying‐xi Zuo,Pan Suo,Lu Bai,Xiaohui Zhang,Yu Wang,Yi-fei Cheng,Xiao‐Jun Huang
标识
DOI:10.1080/08880018.2024.2408535
摘要
Measurable residual disease (MRD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an independent risk factor for relapse in patients with acute lymphoblastic leukemia (ALL). This study aimed to assess the efficacy, safety, and immune reconstitution of chimeric antigen receptor T-cell (CAR-T) therapy in patients with molecular relapse after allo-HSCT. Eleven patients with molecular relapse of B-cell-ALL who underwent CAR-T therapy after allo-HSCT were enrolled. The rate of MRD negativity after a month of CAR-T infusion was 81.8%. Patients who bridged to second-HSCT after CAR-T therapy (
科研通智能强力驱动
Strongly Powered by AbleSci AI